prnewswire.com · 30 jun

Kennametal Names Amanda Cole Vice President and Chief Human Resources Officer; Judith Bacchus to Retire after 20 years at the Company

PITTSBURGH, June 30, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today the appointment of Amanda Cole as Vice President and Chief Human Resources Officer, effective July 21, 2026. Cole brings more than 20 years of experience in leading enterprise-wide transformation, cultural evolution and talent strategy, most recently serving as Vice President of Human Resources, Electrical & Electronic Solutions Business and IT & Digital Functions at Wesco International, Inc. She will succeed Judith Bacchus, who will retire on or about October 1, 2026, after more than 20 years at the company.

zacks.com · 24 jun

Here's Why Kennametal (KMT) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com · 19 jun

Why Kennametal (KMT) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com · 16 jun

Costco & 2 Earnings Acceleration Stocks to Watch for Solid Upside

COST, CMI and KMT stand out for earnings acceleration, with rising EPS growth trends that often precede stronger stock performance.

zacks.com · 11 jun

4 Manufacturing Tools Stocks to Watch Despite Industry Headwinds

The prospects of the Zacks Manufacturing-Tools & Related Products industry are hindered by high operating costs and ongoing supply-chain challenges. SWK, CNM, KMT and EPAC are some promising stocks in the industry.

globenewswire.com · 11 jun

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) CR/CRh in venetoclax-exposed patients – – Deep responses with 80% (24/30) MRD negativity among evaluable CRc responders – – Robust transplant rate with 45% (19/42) of patients proceeding to transplant and 63% (12/19) resuming revumenib post-transplant – – Encouraging durability with median overall survival after transplant not reached –  – Combination was generally well-tolerated – NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the Phase 1/2 SAVE trial of an all-oral regimen of Revuforj® (revumenib), decitabine/cedazuridine, and venetoclax in relapsed or refractory (R/R) NPM1 mutated (NPM1m), KMT2A-rearranged (KMT2Ar), or NUP98-rearranged (NUP98r) acute myeloid leukemia (AML) were published in the Journal of Clinical Oncology and simultaneously presented at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden. Revuforj is the first and only menin inhibitor that is FDA approved for patients one year and older with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options or R/R acute leukemia with a KMT2A translocation as determined by an FDA-authorized test.

zacks.com · 5 jun

Why Is Kennametal (KMT) Down 21.1% Since Last Earnings Report?

Kennametal (KMT) reported earnings 30 days ago. What's next for the stock?

fool.com · 31 may

Kennametal Stock Is Up 50%. Here's What a $181 Million Fund Sale Could Mean

Kennametal delivers advanced tooling and materials for demanding industrial sectors, leveraging innovation and a global customer base.